C12523: ACOT7 Antibody for Neurometabolic Profiling and Drug Discovery
Novelty:
A polyclonal antibody against ACOT7, permitting unraveling the regulation of neuronal lipid balance for the discovery of novel therapeutics for neurological diseases.
Value Proposition:
Dysregulated lipid metabolism has been implicated in a multitude of inborn neuropathologies and neurodegenerative diseases, including Alzheimers and Parkinsons disease. Yet, to date the basic metabolic control of fatty acid metabolism in neurons remains enigmatic. This technology provides a polyclonal antibody against (acyl-CoA thioesterase-7 (ACOT7), a regulator of lipid retention and metabolism critical for neuronal function, allowing elucidating the mechanisms governing neuronal lipid metabolism and discovering novel pharmacological strategies for related neuropathologies. Advantages include:
• Allows dissecting the regulatory mechanisms of neuronal lipid homeostasis
• Facilitates drug discovery for improved management of neurological diseases, e.g. Alzheimers and Parkinsons
Technical Details:
Johns Hopkins researchers have raised a polyclonal antibody against ACOT7 as a tool to study the regulatory mechanisms underlying neuronal lipid metabolism, useful for the development of novel prevention and treatment plans for neurodegenerative diseases. ACOTs are essentially involved in lipid homeostasis by catalyzing the hydrolysis of acyl-CoA into free fatty acids and CoA. Neurons have particularly high cytoplasmic long chain acyl-CoAs hydrolase activity mediated by ACOT7. Importantly, ACOT7 exerts a critical role in preventing neurotoxicity, as demonstrated by an impaired adaptive energy metabolism in acot7-deficient mice. Thus, the herein reported ACOT7 antibody can serve the comprehensive analysis of the alterations in brain fatty acid metabolism immanent for the development of neurological disorders. Given the particular relevance of ACOT7 for neuronal long-chain fatty acid balance, this technology will greatly benefit the development of novel approaches for the prevention and therapy of various neurological diseases
Looking for Partners:
To develop and commercialize this technology as a tool to examine neurometabolic regulation for future drug discovery.
Stage of Development:
Pre-Clinical
Publications/Associated Cases:
Mol Cell Biol. 2013 May;33(9):1869-82.
